Literature DB >> 18283945

A new ivermectin formulation topically kills permethrin-resistant human head lice (Anoplura: Pediculidae).

Joseph P Strycharz1, Kyong Sup Yoon, J Marshall Clark.   

Abstract

This study examines the effectiveness of a new ivermectin formulation for the topical treatment of the human head louse, Pediculus humanus capitis De Geer (Anoplura: Pediculidae). Permethrin-resistant lice originally obtained from south Florida and maintained on an in vitro rearing system were 100% susceptible to ivermectin formulations by using a semiclinical hair tuft bioassay. The formulation was 100% effective at killing lice using 1, 0.5, and 0.25% ivermectin concentrations after 10-min exposures. As judged by the lethal time (LT)50 and LT95 values, 0.5% formulated ivermectin was 3.8 and 3.2 times faster at killing lice, respectively, than 0.5% nonformulated ivermectin, indicating that the formulation may facilitate the penetration of ivermectin into the louse. The hair tuft-based bioassay in conjunction with the in vitro rearing system provides a standardized method to assess the comparative efficacy of pediculicide formulations in a reproducible format that mimics the exposure scenario that occurs on the human scalp.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18283945     DOI: 10.1603/0022-2585(2008)45[75:aniftk]2.0.co;2

Source DB:  PubMed          Journal:  J Med Entomol        ISSN: 0022-2585            Impact factor:   2.278


  15 in total

1.  Ivermectin lipid-based nanocarriers as novel formulations against head lice.

Authors:  Gabriela Ullio-Gamboa; Santiago Palma; Jean Pierre Benoit; Daniel Allemandi; María Inés Picollo; Ariel Ceferino Toloza
Journal:  Parasitol Res       Date:  2017-05-18       Impact factor: 2.289

2.  Endectocides for malaria control.

Authors:  Brian D Foy; Kevin C Kobylinski; Ines Marques da Silva; Jason L Rasgon; Massamba Sylla
Journal:  Trends Parasitol       Date:  2011-07-03

3.  Inhibition of Human Adenovirus Replication by the Importin α/β1 Nuclear Import Inhibitor Ivermectin.

Authors:  Cason R King; Tanner M Tessier; Mackenzie J Dodge; Jason B Weinberg; Joe S Mymryk
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

Review 4.  Utilization of the human louse genome to study insecticide resistance and innate immune response.

Authors:  J Marshall Clark; Kyong Sup Yoon; Ju Hyeon Kim; Si Hyeock Lee; Barry R Pittendrigh
Journal:  Pestic Biochem Physiol       Date:  2014-11-20       Impact factor: 3.963

5.  The effect of ivermectin in seven strains of Aedes aegypti (Diptera: Culicidae) including a genetically diverse laboratory strain and three permethrin resistant strains.

Authors:  K M Deus; K Saavedra-Rodriguez; M P Butters; W C Black; B D Foy
Journal:  J Med Entomol       Date:  2012-03       Impact factor: 2.278

6.  Brief exposures of human body lice to sublethal amounts of ivermectin over-transcribes detoxification genes involved in tolerance.

Authors:  K S Yoon; J P Strycharz; J H Baek; W Sun; J H Kim; J S Kang; B R Pittendrigh; S H Lee; J M Clark
Journal:  Insect Mol Biol       Date:  2011-09-07       Impact factor: 3.585

Review 7.  New chemistries for the control of human head lice, Pediculus humanus capitis: A mini-review.

Authors:  John M Clark
Journal:  Pestic Biochem Physiol       Date:  2021-12-16       Impact factor: 3.963

8.  Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus.

Authors:  Kylie M Wagstaff; Haran Sivakumaran; Steven M Heaton; David Harrich; David A Jans
Journal:  Biochem J       Date:  2012-05-01       Impact factor: 3.857

Review 9.  Insecticide Resistance and Management Strategies in Urban Ecosystems.

Authors:  Fang Zhu; Laura Lavine; Sally O'Neal; Mark Lavine; Carrie Foss; Douglas Walsh
Journal:  Insects       Date:  2016-01-06       Impact factor: 2.769

10.  A new two-phase dimeticone pediculicide shows high efficacy in a comparative bioassay.

Authors:  Jorg Heukelbach; André Asenov; Oliver Liesenfeld; Ali Mirmohammadsadegh; Fabíola A Oliveira
Journal:  BMC Dermatol       Date:  2009-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.